Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Other Accumulated Expenses: 2017-2025

Historic Other Accumulated Expenses for Crinetics Pharmaceuticals (CRNX) over the last 6 years, with Jun 2025 value amounting to $1.8 million.

  • Crinetics Pharmaceuticals' Other Accumulated Expenses rose 66.42% to $1.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $1.8 million, marking a year-over-year increase of 66.42%. This contributed to the annual value of $901,000 for FY2024, which is 72.42% down from last year.
  • Latest data reveals that Crinetics Pharmaceuticals reported Other Accumulated Expenses of $1.8 million as of Q2 2025, which was up 8.05% from $1.7 million recorded in Q1 2025.
  • Crinetics Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $3.3 million during Q4 2023, with a 5-year trough of $335,000 in Q4 2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Other Accumulated Expenses averaged around $1.2 million, with its median value being $984,000 (2023).
  • Per our database at Business Quant, Crinetics Pharmaceuticals' Other Accumulated Expenses skyrocketed by 875.22% in 2023 and then crashed by 72.42% in 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' Other Accumulated Expenses (Quarterly) stood at $939,000 in 2021, then slumped by 64.32% to $335,000 in 2022, then soared by 875.22% to $3.3 million in 2023, then plummeted by 72.42% to $901,000 in 2024, then skyrocketed by 66.42% to $1.8 million in 2025.
  • Its Other Accumulated Expenses stands at $1.8 million for Q2 2025, versus $1.7 million for Q1 2025 and $901,000 for Q4 2024.